Mirum Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Mirum Pharmaceuticals's earnings have been declining at an average annual rate of -15.4%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 77.6% per year.
Key information
-15.4%
Earnings growth rate
12.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 77.6% |
| Return on equity | -47.7% |
| Net Margin | -41.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition
Jul 17Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth
Jul 13
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry
May 28Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
Apr 22Mirum Pharmaceuticals: Advancing On Several Key Fronts
Mar 05There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price
Dec 26What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You
Jun 10Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts
Apr 18Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU
Oct 14Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth
Aug 17Mirum Pharmaceuticals announces $80M stock offering
Aug 09Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent
May 27Is Mirum Pharmaceuticals (NASDAQ:MIRM) In A Good Position To Invest In Growth?
Apr 22Revenue & Expenses Breakdown
How Mirum Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 264 | -109 | 178 | 122 |
| 31 Mar 24 | 224 | -159 | 161 | 111 |
| 31 Dec 23 | 186 | -163 | 146 | 103 |
| 30 Sep 23 | 145 | -164 | 126 | 103 |
| 30 Jun 23 | 116 | -176 | 112 | 103 |
| 31 Mar 23 | 96 | -129 | 100 | 106 |
| 31 Dec 22 | 77 | -136 | 89 | 107 |
| 30 Sep 22 | 52 | -42 | 82 | 104 |
| 30 Jun 22 | 39 | -53 | 76 | 108 |
| 31 Mar 22 | 32 | -70 | 69 | 117 |
| 31 Dec 21 | 19 | -84 | 59 | 131 |
| 30 Sep 21 | 16 | -179 | 47 | 133 |
| 30 Jun 21 | 11 | -153 | 36 | 119 |
| 31 Mar 21 | 0 | -132 | 27 | 102 |
| 31 Dec 20 | 0 | -103 | 23 | 82 |
| 30 Sep 20 | 0 | -84 | 20 | 66 |
| 30 Jun 20 | 0 | -78 | 18 | 62 |
| 31 Mar 20 | 0 | -68 | 15 | 55 |
| 31 Dec 19 | 0 | -53 | 12 | 43 |
| 30 Sep 19 | 0 | -61 | 8 | 32 |
Quality Earnings: MIRM is currently unprofitable.
Growing Profit Margin: MIRM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MIRM is unprofitable, and losses have increased over the past 5 years at a rate of 15.4% per year.
Accelerating Growth: Unable to compare MIRM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MIRM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: MIRM has a negative Return on Equity (-47.67%), as it is currently unprofitable.